Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
42
IDXG Quote, Financials, Valuation and Earnings
Last price:
$1.85
Seasonality move
:
-5.87%
Day range:
$1.82 - $1.85
52-week range:
$0.44 - $1.91
Dividend yield:
0%
P/E ratio:
6.88x
P/S ratio:
0.71x
P/B ratio:
--
Volume:
5.7K
Avg. volume:
12.3K
1-year change:
49.19%
Market cap:
$51.2M
Revenue:
$46.9M
EPS (TTM):
$0.27
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Interpace Biosciences, Inc. has 494.6% upside to fair value with a price target of -- per share.
IDXG vs. S&P 500
-
Over the past 5 trading days, Interpace Biosciences, Inc. has overperformed the S&P 500 by 7.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Interpace Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Interpace Biosciences, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Interpace Biosciences, Inc. reported revenues of $8.8M.
Earnings Growth
-
Interpace Biosciences, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Interpace Biosciences, Inc. reported earnings per share of $0.03.
Enterprise value:
52.1M
EV / Invested capital:
--
Price / LTM sales:
0.71x
EV / EBIT:
11.40x
EV / Revenue:
1.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.75x
Price / Operating cash flow:
6.71x
Enterprise value / EBITDA:
9.68x
Gross Profit (TTM):
$26M
Return On Assets:
30.26%
Net Income Margin (TTM):
9.78%
Return On Equity:
--
Return On Invested Capital:
283.22%
Operating Margin:
13.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $38.3M | $44.6M | $41.9M | $12.3M | $8.8M | |
| Gross Profit | $21.6M | $28.3M | $26M | $7.9M | $5.4M | |
| Operating Income | $1.6M | $7.5M | $4.6M | $2.3M | $1.1M | |
| EBITDA | $2.9M | $8.7M | $5.4M | $2.5M | $1.4M | |
| Diluted EPS | -$0.39 | $1.34 | $0.27 | $0.38 | $0.03 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.1M | $12.7M | $11.4M | $11.1M | $9.1M | |
| Total Assets | $40.3M | $15.3M | $14.3M | $14M | $12M | |
| Current Liabilities | $22.8M | $14.8M | $12.3M | $18.8M | $5.9M | |
| Total Liabilities | $32.4M | $30.4M | $30.4M | $25.2M | $12.3M | |
| Total Equity | $7.9M | -$15.1M | -$16.1M | -$11.1M | -$298K | |
| Total Debt | $12.2M | $10.2M | $13.1M | $6.9M | $864K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.4M | $4.6M | $4.9M | $2.1M | $1.9M | |
| Cash From Investing | -$1M | -$889K | -$447K | -$522K | -$117K | |
| Cash From Financing | -$2.6M | -$6.6M | -$5.1M | -$1.5M | -$900K | |
| Free Cash Flow | $1.8M | $3.7M | $4.4M | $1.6M | $1.8M | |
IDXG
Sector
Market Cap
$51.2M
$24M
Price % of 52-Week High
96.86%
48.22%
Dividend Yield
0%
0%
Shareholder Yield
35.95%
-1.63%
1-Year Price Total Return
49.19%
-22.68%
Beta (5-Year)
1.115
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.81
200-day SMA
Buy
Level
$0.99
Bollinger Bands (100)
Buy
Level
0.83 - 1.49
Chaikin Money Flow
Buy
Level
41K
20-day SMA
Buy
Level
$1.73
Relative Strength Index (RSI14)
Buy
Level
61.33
ADX Line
Buy
Level
25.08
Williams %R
Neutral
Level
-28.5714
50-day SMA
Buy
Level
$1.39
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
2.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.783)
Sell
CA Score
(Annual)
Level (-0.6644)
Sell
Beneish M-Score
(Annual)
Level (-1.1768)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.8935)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.
Stock Forecast FAQ
In the current month, IDXG has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IDXG average analyst price target in the past 3 months is --.
-
Where Will Interpace Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Interpace Biosciences, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Interpace Biosciences, Inc.?
Analysts are divided on their view about Interpace Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Interpace Biosciences, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Interpace Biosciences, Inc.'s Price Target?
The price target for Interpace Biosciences, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IDXG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Interpace Biosciences, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IDXG?
You can purchase shares of Interpace Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Interpace Biosciences, Inc. shares.
-
What Is The Interpace Biosciences, Inc. Share Price Today?
Interpace Biosciences, Inc. was last trading at $1.85 per share. This represents the most recent stock quote for Interpace Biosciences, Inc.. Yesterday, Interpace Biosciences, Inc. closed at $1.85 per share.
-
How To Buy Interpace Biosciences, Inc. Stock Online?
In order to purchase Interpace Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IDXG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IDXG
Sector
P/E ratio
6.88x
23.16x
PEG ratio
--
-0.01x
P/B ratio
--
1.73x
Price / LTM sales
0.71x
1.50x
Growth Metrics
IDXG
Sector
Revenue growth
-28.78%
3.24%
Earnings growth
-91.32%
11.06%
Revenue (5-year growth)
14.14%
6.28%
Earnings forecast
--
-$0.19
Profitability
IDXG
Sector
Profitability FY 2024
$29.9M
$2.7M
Return on invested capital
283.22%
-33.62%
Return on assets
30.26%
-29.68%
Return on equity
--
-39.33%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
IDXG
Sector
Total cash
$1.4M
$25.1M
Short term investments
--
$23.9M
Total assets
$14.8M
$72.8M
Long term debt
$864K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is down 39.93% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 36.39% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 35.78% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
